March 8, 2018 / 12:17 PM / 3 months ago

BRIEF-Cyteir Therapeutics Secures $29 Mln Series B To Advance Novel, Molecularly Targeted Therapies For Cancer And Autoimmune Diseases

* CYTEIR THERAPEUTICS SECURES $29 MILLION SERIES B TO ADVANCE NOVEL, MOLECULARLY TARGETED THERAPIES FOR CANCER AND AUTOIMMUNE DISEASES

* CYTEIR THERAPEUTICS - ANNOUNCED CLOSE OF A $29 MILLION SERIES B PREFERRED STOCK FINANCING Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below